OTCMKTS:ATBPD Antibe Therapeutics (ATBPD) Stock Price, News & Analysis → Beta testers blew this thing up (From Prosper Trading Academy) (Ad) Free ATBPD Stock Alerts $0.22 0.00 (0.00%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$0.22▼$0.2250-Day Range$0.19▼$0.2252-Week Range$2.64▼$3.50VolumeN/AAverage Volume29,710 shsMarket Capitalization$83.59 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get Antibe Therapeutics alerts: Email Address Ad Prosper Trading AcademyBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and finds hot stocks that you probably have never even heard of… …it recommends the best potential strategy to use on the names it finds (with historical data to prove it)Click Here To Read More About This Game Changing AI Tool About Antibe Therapeutics Stock (OTCMKTS:ATBPD)Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.Read More ATBPD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATBPD Stock News HeadlinesApril 1, 2024 | marketwatch.comAntibe Therapeutics Shares Down on Clinical Hold on Otenaproxesul by U.S. RegulatorApril 1, 2024 | marketwatch.comAntibe Therapeutics Drug Otenaproxesul Placed on Clinical Hold by FDAJune 18, 2024 | Prosper Trading Academy (Ad)Beta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and finds hot stocks that you probably have never even heard of… …it recommends the best potential strategy to use on the names it finds (with historical data to prove it)June 29, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Antibe Therapeutics (OtherATBPF), Terns Pharmaceuticals (TERN) and Aquestive Therapeutics (AQST)See More Headlines Receive ATBPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:ATBPD CUSIPN/A CIKN/A Webwww.antibethera.com Phone416 922 3460FaxN/AEmployees47Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,540,000.00 Net Margins-273.96% Pretax MarginN/A Return on Equity-150.49% Return on Assets-98.51% Debt Debt-to-Equity RatioN/A Current Ratio5.97 Quick Ratio5.42 Sales & Book Value Annual Sales$7.51 million Price / Sales11.13 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book2.16Miscellaneous Outstanding Shares387,000,000Free FloatN/AMarket Cap$83.59 million OptionableNot Optionable Beta0.57 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Daniel Marcel Legault (Age 62)Pres, CEO, Sec. & Director Dr. John Lawrence Wallace M.B.A. (Age 63)M.Sc., MSc, Ph.D., MBA, Founder, Chief Scientific Officer & Director Mr. Alain Wilson M.B.A.MBA, Chief Financial OfficerDr. David James Vaughan (Age 70)Chief Devel. Officer Mr. Scott Curtis C.F.A.M.Eng, CFA, Exec. VPMs. Christina Cameron B.B.A.VP of Investor RelationsMr. Philip SternVP of CommunicationsDr. Rami Batal M.B.A.Ph.D., Chief Commercial OfficerMs. Ella Korets Smith M.B.A.M.Sc., Head of Regional Bus. Devel.Dr. Joseph Stauffer (Age 54)Chief Medical Officer More ExecutivesKey CompetitorsAmarinNASDAQ:AMRNXeris BiopharmaNASDAQ:XERSEmergent BioSolutionsNYSE:EBSAlto NeuroscienceNYSE:ANROSilverback TherapeuticsNASDAQ:SBTXView All Competitors ATBPD Stock Analysis - Frequently Asked Questions How have ATBPD shares performed in 2024? Antibe Therapeutics' stock was trading at $0.6820 at the beginning of the year. Since then, ATBPD shares have decreased by 68.3% and is now trading at $0.2160. View the best growth stocks for 2024 here. How do I buy shares of Antibe Therapeutics? Shares of ATBPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ATBPD) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antibe Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.